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Abstract
Background: the treatment of infectious diseases is still an important and chal-
lenging problem due to the emergence of numerous infectious diseases and in-
creasing number of multi-drug resistant microbial pathogens which cause a variety 
of illnesses ranging from hospital-acquired pneumonia, bloodstream infections and 
urinary tract infections from catheters, abdominal infections and even meningitis. 
Material and Methods: the main objective of the present study was to evaluate 
the antimicrobial efficacy of the synthesized 2-azetidinones against standard and 
resistant bacterial strains, assayed in vitro by the two-fold broth dilution technique.
Results: the tested 2-azetidinones exhibited antimicrobial efficacy comparable 
to the standard drugs Ampicillin and Griseofelvin. Among the tested compounds, 
N-[3-chloro-2-(2,5-dimethoxyphenyl)-4-oxoazetidin-1-yl] pyridine-4-carboxamide 
(5o) exhibited the highest activity with MIC of 6.25 µg/mL (tested gram +ve and 
gram -ve bacteria), 1.56 µg/mL (Aspergillus niger) and 3.12 µg/mL (Aspergillus 
terrus and penicillum chrysogenum) respectively. Also the screened compounds, 
5d, 5f, 5h, 5j and 5o exhibited pronounced activity against resistant strains of E. 
coli, S. aureus and K. pneumonia which were resistant to the standard antibiotic 
amoxycillin. The 2-azetidinones can thereby prove to be beneficial towards the 
development of anti-infectives for the treatment of infections caused by drug 
resistant microorganisms.
Keywords: 2-Azetidinone, Antimicrobial, Multi-drug resistant strains.
Introduction
The treatment of infectious diseases still remains an impor-
tant and challenging problem because of a combination of 
factors including emerging infectious diseases and the in-
creasing number of multi-drug resistant microbial pathogens 
with particular relevance for Gram positive bacteria [1, 2]. 
Bacterial resistance has currently become a grave concern for 
physicians. Resistant bacteria, particularly Staphylococci, En-
terococci, Klebsiella pneumoniae and Pseudomonas species 
are becoming common in healthcare institutions [3-5]. Bacte-
rial resistance often results in treatment failure, which can 
have serious consequences, especially in critically ill patients. 
Inadequate empiric antibacterial therapy has been associated 
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with increased mortality rates in patients with bloodstream 
infections due to these resistant microorganisms [6, 7].
Multidrug-resistant Gram positive pathogens, such as methi-
cillin-resistant Staphylococcus aureus (MRSA) and vancomycin 
resistant Staphylococcus aureus (VRSA) have become a seri-
ous problem in the medical community [8-10]. A study found 
that the rate of developed mutations in Escherichia coli is 
of the order of 10−5 per genome per generation, which is 
1000 times as high as previous estimates, a finding which 
may be significant for the study and management of bacte-
rial antibiotic resistance [11]. Antibiotic-resistant E. coli may 
also pass on the genes responsible for antibiotic resistance to 
other species of bacteria, such as S. aureus, through a process 
called horizontal gene transfer. E. coli bacteria often carry 
multiple drug-resistance plasmids, and under stress, readily 
transfer these plasmids to other species. Thus, E. coli and the 
other enteric bacteria are important reservoirs of transferable 
antibiotic resistance [12]. Extended-spectrum beta-lactamase 
producing E. coli is also highly resistant to an array of anti-
biotics, and infections by these strains are difficult to treat 
[13]. Infection with carbapenem-resistant Enterobacteriaceae 
(CRE), especially carbapenem-resistant Klebsiella pneumonia 
(CRKP) is also emerging as an important challenge in health-
care settings [14, 15]. Antibacterial drug resistance also places 
an added burden on healthcare costs, although its full eco-
nomic impact remains to be determined. 
The 2-azetidinone (β-lactam) ring system is the common 
structural feature of a number of broad spectrum β-lactam 
antibiotics, including penicillins, cephalosporins, carbapen-
ems, nocardicins, monobactams, clavulanic acid, sulbactam 
and tazobactam; which have been widely used as chemo-
therapeutic agents to treat bacterial infections and micro-
bial diseases [16]. The success of these antibiotics is due to 
their bactericidal activity, good pharmacokinetics and low 
host toxicity. Research efforts in this class led to prepara-
tion of semi-synthetic and synthetic monobactam analogues 
(2-azetidinones) like aztreonam and carumonam, active most-
ly against Gram-negative bacteria. 
Currently several 2-azetidinones are being extensively stud-
ied as promising anti-bacterial agents. Recently Singh et al. 
described the synthesis of new 1-alkyl/cyclohexyl-3, 3-dia-
ryl-1’-methylspiro [azetidine-2, 3’-indoline]-2’, 4-diones with 
promising antibacterial activity [17]. Halve et al. developed 
a series of 3-chloro-4-(3-methoxy-4-acetyloxyphenyl)-1-[3-
oxo-3-(phenylamino) propanamido] azetidin-2-ones, and 
3-chloro-4-[2-hydroxy-5-(nitro substituted phenylazo)phenyl]-
1-phenylazetidin-2-ones and assayed there in vitro growth 
inhibitory activity against pathogenic micro-organisms [18], 
2-{2-[3-chloro-2-(aryl)-4-oxoazetidin-1-ylamino]-acetylamino}
benzothiazole-6-carboxylic acid derivatives were synthesized 
by Chavan et al. with good to moderate antibacterial activity 
[19]. Various 4-alkylidenazetidin-2-ones [20], 1’-[(Benzimid-
azol-2-yl)thioacetamidyl-3-(phenylamino)propanamido]azeti-
din-2-ones [21], 1-substituted-3, 3- diaryl- 4- [2’-(o-diarylacyl) 
hydroxyphenyl]-2-azetidinones [22], were evaluated for their 
antibacterial activity with potent activity against multi-drug 
resistant pathogens. The 2-azetidinone-based heterocyclics 
are also reported to exhibit β-lactamase inhibitory activity 
[23, 24]. Due to their potential activity, the 2-azetidinone scaf-
fold represents an attractive target for contemporary organic 
synthesis [25].
On the basis of the above findings, a series of N-[3-chloro-
2-(substituted aromatic)-4-oxoazetidin-1-yl] pyridine-4-car-
boxamide analogues containing the 2-azetidinone ring were 
synthesized by our previously reported green route method 
of sonication from Schiff’s bases of Isoniazid (INH).
Looking to the promising antimicrobial activity of some 
2-azetidinones and in continuation of our earlier studies 
(Thomas, AB, Nanda, RK, Kothapalli, LP and Hamane, SC. 
Synthesis and biological evaluation of Schiff’s bases and 
2-azetidinones of isonicotiniyl hydrazone as potential anti-
depressant and nootropic agents. Arabian Journal Chemistry 
[In Press]), we were stimulated to explore the synthesized 
2-azetidinone analogues for their antibacterial activity against 
resistant bacterial strains obtained from clinical isolates across 
hospitals in India.
Materials and Methods
Bacterial strains
The standard microbial strains selected for the study include 
Bacillus subtilis (ATCC 9372, NCIM 2951), Bacillus anthracis 
(ATCC 14579, NCIM B9373), Staphylococcus aureus (ATCC 
6538P, NCIM 2079), Escherichia coli(ATCC 9637,NCIM2563), 
Enterobacter aerogenus (NCIM 5139), Pseudomonas aerogi-
nosa (ATCC 19429, NCIM 2036), Aspergillus niger (ATCC 
10864, NCIM 616), Penicillium chrysogenum (ATCC 10002, 
NCIM 738) and Aspergillus terrus ATCC10020,NCIM657) 
which were procured from National Collection of Industrial 
Microorganisms (NCIM), Pune, India.
Resistant strains of E. coli, S. aureus and K. pneumonia were 
clinical isolates collected from hospitals across India (Ob-
tained from MTCC Chandigarh, India; Escherichia coli: ATCC 
no:  25922, Klebsiellia pneumoniae: 29665, Staphylococcus 
aureus: 12598). The resistant strains received in lyophilized 
form, were revived and then sub cultured on Blood Agar 
medium. The colonies were initially identified by presump-
tive identification tests which included gram staining, motil-
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ity, catalase, oxidase and slide coagulase testing, and they 
were further subjected to biochemical tests to confirm their 
identity. All bacterial strains were preserved in 15% glycerol 
broth at -80°C, thawed and sub cultured as test required. 
Drugs 
Ampicillin (Neiss Labs Ltd., Mumbai, India), amoxycillin (Hin-
dustan Antibiotics Ltd., Pune, India) and griseofulvin (Merit 
Organics Ltd., Mumbai, India) were employed as the stan-
dard drugs for anti-microbial screening. N’-[(1Z)-(substituted 
aromatic) methylidene] pyridine-4-carbohydrazide (3a-q) 
and N-[3-chloro-2-(substituted aromatic)-4-oxoazetidin-1-yl] 
pyridine-4-carboxamides (5b-j, l-q) were synthesized in our 
laboratory and characterised by suitable spectroscopic and 
chromatographic tools.
Chemistry
N’-[(1Z)-(aryl/substituted aryl)methylidene] 
pyridine-4-carbohydrazides (Schiff’s base)
The synthesis of compounds (3a-q) was performed according 
to our previously reported procedure [Scheme 1] [26]. The 
crude products upon recrystallisation from alcohol gave the 
pure Schiff’s bases (3a–q). The synthesised compounds were 
characterised on the basis of their spectral and analytical data 
(UV, IR, 1H NMR, MS, CHN). 
N-[3-chloro-2-(substitutedaryl)-4-oxoazetidin-1-
yl]pyridine-4-carboxamide(2 azetidinones) using 
Schiff’s bases 
The 2-azetidinones (5b-j,l-q) were synthesized by our repor-
ted green route method of sonication [Scheme 2] [27]. The 
crude products on recrystallisation from suitable solvent yiel-
ded the pure 2-azetidinones of isonicotinoyl hydrazones. The 
synthesized compounds were characterized on the basis of 
their spectral and analytical data (UV, IR, 1H NMR, MS, and 
CNH).
Evaluation of antimicrobial efficacy of 
compounds against standard anti-microbial 
strains
The antimicrobial susceptibility testing of the synthesized com-
pounds (3a-q; 5b-j, l-q) were assayed in vitro by the two-fold 
broth dilution technique. Test drug solutions were dissolved 
in dimethylsulfoxide, diluted in culture media (Mueller–Hinton 
broth for bacteria and Sabouraud Liquid medium for fungi) 
to obtain final concentrations in the range of 0.78-1000 µg 
/mL and then assayed to determine the minimal inhibitory 
concentration (MIC, µg/mL). The MIC was determined as the 
lowest concentration that prevented visible growth of micro-
organisms after incubation for a specified period at a fixed 
temperature. The amount of inocula employed was 5 x 104 
bacteria/mL and 1 x 103 fungi/mL. The MIC’s were read after 
incubation at 37± 0.5° for antibacterial activity for 24 h and 
48 h at 28 ± 0.5° for antifungal activity [28]. 
Table 1. Antibiotic sensitivity pattern of resistant bacterial strains obtained from clinical isolates.
Antibiotic E.coli K. pneumoniae S. aureus
Amoxycillin R R R
Erythromycin R R S
Penicillin R R R
Amoxycillin + R R R
Cephalexin R R R
Ciprofloxacin R R R
Gentamicin S S S
Cefotaxime R R R
Cefuroxime S S R
Linizolid S S S
Ofloxacin R R S
Levofloxacin S S S
Netilmicin S S S
S: sensitive; R: resistant.
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Evaluation of antibacterial potency against resistant bacterial 
strains obtained from clinical isolates
The most potent compounds (5d,f,h,j,o) of the 2-azetidinone 
series were further evaluated for their activity against resis-
tant strains of E. coli, S. aureus and K. pneumonia obtained 
from clinical isolates across India. The antibiotic sensitivity 
pattern for the bacterial strains are summarised in Table 1.
The antibiotic sensitivity testing was performed according to 
the standard Kirby Bauer method using Hi Media antibiotic 
discs. Sensitivity was analyzed by the presence/absence of 
zone of inhibition and comparison of the diameter of zone 
of inhibition with reference to the standard values. The an-
timicrobial testing was carried out by the broth dilution te-
chnique, and the minimum inhibitory concentrations were 
determined [29)]. 
Results and Discussion
Chemistry
The synthetic strategies adopted to obtain the intermediate 
and target compounds are illustrated in Schemes 1 and 2 
respectively. 
Scheme 1. Microwave assisted synthesis of intermedi-
ate Schiff’s bases of INH (3a-q)
Reagents and conditions: i. H2O, MWI, Power level 3 
(240 W, 35% irradiation).
Scheme 2. Synthesis of 2-azetidinones (5b-j,l-q) using 
Schiff’s bases
Reagents and conditions: ii. MS3A, Et3N, CH2Cl2, sonica-
tion.
Table 2. Synthesized Schiff’s bases of INH (3a-q).
Compound  
Code Imines(3a-q) Nature of R
3a N’-[(1Z)-phenylmethylidene]pyridine-4-carbohydrazide C6H5
3b N’-[(1Z)-(2-hydroxyphenyl)methylidene]pyridine-4-carbohydrazide C6H5O
3c N’-[(1Z)-(4-hydroxyphenyl)methylidene]pyridine-4-carbohydrazide C6H5O
3d N’-[(1Z)-(4-chlorophenyl)methylidene]pyridine-4-carbohydrazide C6H4Cl
3e N’-[(1Z)-(3-chlorophenyl)methylidene]pyridine-4-carbohydrazide C6H4Cl
3f N’-[(1Z)-(4-nitrophenyl)methylidene]pyridine-4-carbohydrazide C6H4NO2
3g N’-[(1Z)-(3-nitrophenyl)methylidene]pyridine-4-carbohydrazide C6H4NO2
3h N’-[(1Z)-(2-nitrophenyl)methylidene]pyridine-4-carbohydrazide C6H4NO2
3i N’-[(1Z)-(4-fluorophenyl)methylidene]pyridine-4- carbohydrazide C6H4F
3j N’-[(1Z)-(4-methoxyphenyl)methylidene]pyridine-4-carbohydrazide C7H7O
3k N’-[(1Z,2E)-3-phenylprop-2-en-1-ylidene]pyridine-4-carbohydrazide C8H7
3l N’-[(1Z)-(4-hydroxy-3-methoxyphenyl)methylidene]pyridine-4-carbohydrazide C7H7O2
3m N’-[(1Z)-furan-2-ylmethylidene]pyridine-4-carbohydrazide C4H3O
3n N’-{(1Z)-[4-(dimethylamino)phenyl]methylidene}pyridine-4-carbohydrazide C8H10N
3o N’-[(1Z)-(2,5-dimethoxyphenyl)methylidene]pyridine-4-carbohydrazide C8H9O2
3p N’-[(1Z)-(5-nitrothiophen-2-yl)methylidene]pyridine-4-carbohydrazide C4H2NO2S
3q N’-[(1Z)-(2-hydroxynaphthalen-1-yl)methylidene]pyridine-4-carbohydrazide C9H7O
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Substitution at R: 3a:C6H5; 3b/5b: 2-OHC6H4; 3c/5c: 
4-OHC6H4; 3d/5d:4-ClC6H4; 3e/5e: 4-ClC6H4;3f/5f:4-
NO2C6H4;3g/5g:3-NO2C6H4;3h/5h:2-NO2C6H4;3i/5i:4-
FC6H4;3 j / 5 j :4 - OCH3C6H4;3k :C8H7;3 l / 5 l :4 - OH ,3 -
OCH3C6H3;3m/5m:2-C4H3O;3n/5n:4-(CH3)2NC6H4; 3o/5o: 
2,5(OCH3)2C6H3; 3p/5p: C4H2NO2S; 3q/5q:C9H7O
The N’-[(1Z)-(substituted aromatic) methylidene] pyridine-4-
carbohydrazide(3a-q) were prepared in excellent yields in a one 
step reaction (Scheme 1) of isonicotinyl hydrazone (INH,1) with 
various substituted aryl/hetero aryl aldehydes (2a-q) in water 
using our previously reported microwave irradiation method 
in shorter reaction times (6-9 mins) with improved yields 
(86.7-99.2%). The synthesized intermediates were utilised 
for the synthesis of N-[3-chloro-2-(substitutedaromatic)-4-
oxoazetidin-1-yl]pyridine-4-carboxamides(5b-j,l-q) containing 
2-azetidinone nucleus by sonication (Scheme 2) with high 
yields (81.0-95.2%) in shorter reaction times (20-45 min). 
The compounds synthesized are enlisted in Tables 2 and 
3 respectively. Structures of the obtained compounds have 
been ascertained on the basis of their IR, 1H NMR and Mass 
spectral assignments. 
Evaluation of antimicrobial efficacy of 
compounds against standard anti-microbial 
strains
The antimicrobial activity of all compounds (3a-q; 5b-j,l-q) 
determined in terms of MIC, µg/mL are presented in Tables 
4 and 5 respectively. As reported earlier [30], the investigated 
intermediate Schiff’s bases displayed very weak inhibition of 
growth of both bacteria and fungi with MIC in the range of 
125-1000µg/mL.
The 2-azetidinones however exhibited moderate anti-micro-
bial activity as compared to their respective Schiff’s bases 
with MIC in the range of 6.25-200µg/mL against the tested 
bacterial strains and 1.56-200µg/mL against the tested fungal 
strains. 
Among the N-[3-chloro-2-(substitutedaromatic)-4-oxoaz-
etidin-1-yl]pyridine-4-carboxamide derivatives tested, com-
pound 5o with a 2,5 dimethoxy substituted phenyl group at 
C-4 position of the azetidinone ring exhibited highest activity 
with MIC of 6.25 µg/mL against the tested bacterial strains 
(both gram +ve and gram –ve bacteria). However compound 
5o exhibited more pronounced antifungal activity with MIC 
of 1.56 µg/mL against A. niger and 3.12 µg/mL against both 
A. terrus and P. chrysogenum. 
Table 3. Synthesized 2-azetidinones (5b-j,l-q).
Compound 
Code 2-Azetidinones Nature of R
5b N-[3-chloro-2-(2-hydroxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H5O
5c N-[3-chloro-2-(4-hydroxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H5O
5d N-[3-chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4Cl
5e N-[3-chloro-2-(3-chlorophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4Cl
5f N-[3-chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4NO2
5g N-[3-chloro-2-(3-nitrophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4NO2
5h N-[3-chloro-2-(2-nitrophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4NO2
5i N-[3-chloro-2-(4-fluorophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C6H4F
5j N-[3-chloro-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C7H7O
5l N-{3-chloro-2-oxo-4-[(E)-2-phenylethenyl]azetidin-1-yl}pyridine-4-carboxamide C8H7
5m N-[3-chloro-2-(4-hydroxy-3-methoxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C4H3O
5n N-(3-chloro-2-furan-2-yl-4-oxoazetidin-1-yl)pyridine-4-carboxamide C8H10N
5o N-[3-chloro-2-(2,5-dimethoxyphenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C8H9O2
5p N-[3-chloro-2-(5-nitrothiophen-2-yl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C4H2NO2S
5q N-[3-chloro-2-(2-hydroxynaphthalen-1-yl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide C9H7O
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Table 4. Antimicrobial activity of Schiff’s bases of INH.
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3a-i >250b >250 b >250 b >250 b >250 b >250 b >250 b >250 b >250 b
3j 250 >250 b >250 b 250 >250 b >250 b >250 b >250 b >250 b
3k-l >250 b >250 b >250 b >250 b >250 b >250 b >250 b >250 b >250 b
3m >250 b >250 b 250 >250 b >250 b >250 b >250 b >250 b >250 b
3n >250 250 250 250 >250 b 250 >250 b 250 >250
3o 250 125 250 125 250 250 250 125 125
3p 250 b 250 250 250 250 250 250 250 250
3q >250b >250 >250 b >250 b >250 b >250 b >250 b >250 b >250 b
Ampc 3.13 3.13 3.13 3.13 3.13 3.13  --  --   --
Gred -- -- -- -- -- -- 3.13 3.13 3.13
aMIC: Lowest concentration of an antimicrobial agent that significantly inhibits the visible growth of microorganism after a period of 
incubation ;b No inhibition up to a highest concentration of 250 µg/ml; cAmp: Ampicillin; dGre: Greseofulvin.
Table 5. Antimicrobial activity of synthesized 2-azetidinones.
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5b 25 12.5 25 25 25 25 12.5 12.5 25
5c 12.5 25 25 12.5 12.5 12.5 25 12.5 12.5
5d 12.5 12.5 25 12.5 25 25 12.5 12.5 12.5
5e 25 25 100 100 200 100 200 100 100
5f 25 12.5 25 25 25 25 12.5 25 12.5
5g 100 50 25 200 100 50 200 100 100
5h 6.25 12.5 12.5 12.5 25 12.5 25 12.5 12.5
5i 12.5 25 25 12.5 12.5 25 12.5 25 25
5j 12.5 6.25 12.5 12.5 12.5 12.5 6.25 25 6.25
5l 12.5 12.5 12.5 25 12.5 25 12.5 25 12.5
5m 25 25 25 25 12.5 25 12.5 25 25
5n 25 12.5 25 25 25 25 12.5 12.5 12.5
5o 6.25 6.25 6.25 6.25 6.25 6.25 1.56 3.12 3.12
5p 25 50 25 100 200 100 200 50 50
5q 100 100 25 100 200 200 200 100 25
Ampc 3.13 3.13 3.13 3.13 3.13 3.13 -- -- --
Gred -- -- -- -- -- -- 3.13 3.13 3.13
aMIC:  Lowest concentration of an antimicrobial agent that significantly inhibits the visible growth of microorganism after a period of 
incubation ;b No inhibition up to a highest concentration of 250 µg/ml; cAmp: Ampicillin; dGre: Greseofulvin.
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It was observed that compound 5h, N-[3-chloro-2-(2-
nitrophenyl)-4-oxoazetidin-1-yl]pyridine-4-carboxamide exhi-
bited good inhibitory activity with MIC of 6.25 µg/ml against 
the gram-positive bacteria strain B. subtilis.
 
Evaluation of antibacterial potency against 
resistant bacterial strains obtained from clinical 
isolates
The most potent compounds of the 2-azetidinone series 
(5d,f,h,j,o) were further evaluated against drug resistant bac-
terial strains E. coli, S. aureus and K. pneumonia obtained 
from clinical isolates. The standard antibiotic Amoxycillin was 
found to be resistant to the tested bacterial strains, E. coli, 
S. aureus and K. pneumonia. In comparison, the screened 
2-azetidinones exhibited moderate inhibitory potency against 
the resistant strains with MIC ranging from 62.5-500 µg/mL 
(Table 6). Compound 5d, exhibited inhibitory activity with 
MIC of 62.5 µg/ml against resistant bacterial strain, E. coli. 
Table 6.   timicrobial activity of 2-azetidinones against resis-
tant bacterial strains.
Minimum Inhibitory Concentration (MIC) in μg/mL
2-Azetidinones S.aureus* E. coli* K. pneumonia*
5d 62.5 125 125
5f 125 125 125
5h 250 500 125
5j 125 125 125
5o 125 125 125
Am R R R
*  Resistant strains obtained from clinical isolates; am: Amoxycillin; 
R: Resistant.
Conclusions
In the present study, the antimicrobial efficacies of 2-azetid-
inones of isoniazid have been described. The synthesis of 
the N’-[(1Z)-(substituted aromatic) methylidene] pyridine-4-
carbohydrazides and N-[3-chloro-2-(substituted aromatic)-4-
oxoazetidin-1-yl] pyridine-4-carboxamides were carried out by 
us using green route methods of microwave irradiation and 
sonication resulting in improved yield with shorter reaction 
times. N-[3-chloro-2-(2,5-dimethoxyphenyl)-4-oxoazetidin-1-
yl]pyridine-4-carboxamide (5o) exhibited the highest activi-
ty against the tested standard bacterial and fungal strains. 
The 2-azetidinones (5d,f,j,o) containing electron withdrawing 
(chloro, nitro, methoxy) substituent’s on phenyl ring, exhibi-
ted pronounced inhibitory activity against amoxycillin resi-
stant bacterial strains, E. coli, S. aureus and K. pneumonia. 
The 2-azetidinones thereby can prove to be beneficial to-
wards the development of anti-infectives for the treatment of 
infections caused by drug resistant microorganisms.
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